Literature DB >> 19322931

DNA-guided hepatitis B treatment: viral load is insufficient with few exceptions.

Pankaj Jain.   

Abstract

In DNA-guided hepatitis B treatment, viral load is insufficient, and requires other viral markers for treatment of hepatitis B patients as in patients with acute exacerbation of chronic hepatitis B, end-stage renal disease on dialysis, human immunodeficiency virus co-infected patients. There are exceptions to this rule: a residual level hepatitis B virus (HBV) DNA at 24 wk predicts beneficial outcome and reduced resistance at 1 year. The genotypic viral resistance to antiviral agents and occult HBV infection can be determined by HBV-DNA levels.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19322931      PMCID： PMC2665152          DOI： 10.3748/wjg.15.1530

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  17 in total

1.  Occult hepatitis B virus infection: a hidden menace?

Authors:  H S Conjeevaram; A S Lok
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

2.  Chronic hepatitis B.

Authors:  A S Lok; B J McMahon
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

3.  Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection.

Authors:  I Cacciola; T Pollicino; G Squadrito; G Cerenzia; D Villari; R de Franchis; T Santantonio; S Brancatelli; G Colucci; G Raimondo
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

4.  Detection of serum HBV-DNA by polymerase chain reaction (PCR) in patients before reactivation of chronic hepatitis B.

Authors:  S Gayno; P Marcellin; M A Loriot; M Martinot-Peignoux; P Levy; S Erlinger; J P Benhamou
Journal:  J Hepatol       Date:  1992-03       Impact factor: 25.083

Review 5.  Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements.

Authors:  Chien-Jen Chen
Journal:  J Hepatol       Date:  2005-01-22       Impact factor: 25.083

6.  Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.

Authors:  G J Webster; S Reignat; M K Maini; S A Whalley; G S Ogg; A King; D Brown; P L Amlot; R Williams; D Vergani; G M Dusheiko; A Bertoletti
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

Review 7.  Management of antiviral resistance in patients with chronic hepatitis B.

Authors:  Stephen Locarnini; Angelos Hatzakis; Jenny Heathcote; Emmet B Keeffe; T Jake Liang; David Mutimer; Jean-Michel Pawlotsky; Fabien Zoulim
Journal:  Antivir Ther       Date:  2004-10

8.  Survival in chronic hepatitis B. An analysis of 379 patients.

Authors:  J I Weissberg; L L Andres; C I Smith; S Weick; J E Nichols; G Garcia; W S Robinson; T C Merigan; P B Gregory
Journal:  Ann Intern Med       Date:  1984-11       Impact factor: 25.391

9.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

Authors:  Chloe L Thio; Eric C Seaberg; Richard Skolasky; John Phair; Barbara Visscher; Alvaro Muñoz; David L Thomas
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

10.  Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.

Authors:  George V Papatheodoridis; Evangelini Dimou; Andreas Laras; Vassilios Papadimitropoulos; Stephanos J Hadziyannis
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425
View more
  1 in total

1.  Full-length hepatitis B virus sequences from naïve patients with fluctuation of viral load during ADV monotherapy.

Authors:  Yongwei Li; Mingfen Zhu; Yunwei Guo; Wei Chen; Gang Li
Journal:  Virus Genes       Date:  2009-12-12       Impact factor: 2.332
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.